Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-02
2010-10-05
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07807711
ABSTRACT:
The invention relates to an acidic cannabinoid for medical use and to a cannabis extract comprising an acidic cannabinoid. The extract may comprise one or more compounds selected from the group consisting of cannabidiolic acid (CBD-A), cannabidiol (CBD), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabinolic acid (CBN-A) and cannabinol. The invention further relates to a method for preparing a preparation comprising extracting an acidic cannabinoid from cannabis.
REFERENCES:
patent: 2002/0086438 (2002-07-01), Elsohly et al.
patent: 2004/0049059 (2004-03-01), Mueller
patent: 2 384 707 (2003-08-01), None
patent: 2000-078979 (2000-03-01), None
patent: WO 89/01332 (1989-02-01), None
Derwent-ACC-No. 2000-285930, Abstract of JP 2000-078979A published Mar. 21, 2000.
Bhargava, “Potential Therapeutic Applications of Naturally Occurring and Synthetic Cannabinoids,”Gen. Pharmac., 9(4):195-213 (1978).
Izeboud et al., “Participation of β-Adrenergic Receptors on Macrophages in Modulation of LPS-Induced Cytokine Release,”J. Rec. Sign. Tr. Research, 19(1-4):191-202 (1999).
Mosmann, “Rapid Colorimetric Assay for Cellular Growth and Survival: . . . ,”J Immunol. Methods, 65:55-63 (1983).
Nagelkerken et al. “FcR Interactions Do Not Play a Major Role in Inhibition of Experimental Autoimmune Encephalomyelitis by Anti-CD154 Monoclonal Antibodies,”J. Immunol., 173:993-999 (2004).
Visser et al., “Increased Sensitivity to Glucocortoids in Peripheral Blood Mononuclear Cells of Chronic Fatigue Syndrome Patients . . . ”J. Investigative Medicine, 49(2):195-204 (2001).
Yotoriyama, et al., “Comparison of Pharmacological Activity in Mice of Different Cannabis Extracts from CBDA and THCA Strains,”, Eisai Kagaku, vol. 37 (6), p. 507-511 (1991).
Kinzer, et al., “The Fate of the Cannabinoid Components of Marihuana During Smoking,” Bulletin on Narcotics, vol. XXVI, No. 3, Jul.-Sep. 1974, 41-54.
Stott, et al., “Cannabinoids for the Pharmaceutical Industry,” Euphytica 140: 83-93, 2004.
Doornbos Robert Paul
Korthout Henricus Adriaan A. J.
Verhoeckx Kitty Catharina M.
Wang Mei
Witkamp Rentje Frederik
Dentz Bernard
Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk On
LandOfFree
Medicinal acidic cannabinoids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicinal acidic cannabinoids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicinal acidic cannabinoids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4213947